Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Nurix Therapeutics Inc

Billionaire investor David Tepper&#8216;s Appaloosa Management reduced its stake in Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) by 5% in the third quarter, despite his recent public enthusiasm for Chinese investments, according to regulatory filings released Thursday.
What Happened: The reduction comes just months after Tepper declared that he <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41050711/stocks-rise-as-china-signals-more-stimulus-billionaire-david-tepper-bets-big-on-everythi">would buy &#8220;everything&#8221; China-related</a> amid Beijing&#8217;s stimulus efforts. Despite the trim, Alibaba remains Appaloosa&#8217;s largest holding, representing 15.75% of its $6.7 billion equity portfolio.
The hedge fund&#8217;s third-quarter moves reveal a complex strategy toward Chinese investments. While reducing positions in the iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>), and Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), Tepper more than doubled his stake in PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) and increased positions in JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and KE Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>).
The filing also revealed significant reductions in major U.S. technology holdings. Appaloosa sold 275,000 shares of Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), representing an 8.59% reduction while cutting its Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) position by 211,356 shares, or 21.89%. The fund also reduced its stake in Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) by 310,000 shares, a 49.6% decrease, and trimmed its position in Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
See Also: <a href="https://www.benzinga.com/news/global/24/11/41998381/tesla-earnings-will-be-hit-hardest-if-7500-ev-credit-is-cut-warns-gary-black-citing-80-dependence-on-ev-sales-please-do-the-math">Tesla Earnings Will Be Hit Hardest If $7.5K EV Credit Gets Cut By Trump, Warns Gary Black: &#8216;Do The Math&#8217;</a>
Why It Matters: Overall, Tepper&#8217;s exposure to Chinese stocks and ETFs increased to 38% of his equity portfolio in the third quarter, up from 26% in the previous quarter. This positions him, alongside Scion Asset Management&#8216;s Michael Burry, as one of the few prominent hedge fund managers <a href="https://www.benzinga.com/markets/equities/24/10/41248334/big-short-investor-michael-burrys-china-bet-pays-off-as-top-picks-surge-nearly-60-in-2-months">maintaining significant Chinese market exposure</a>. 
These portfolio adjustments come as Chinese stocks face headwinds from disappointing fiscal policies and persistent economic challenges, including weak consumer spending and an unstable property market. Market observers note that geopolitical tensions and potential tariff increases add further <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">uncertainty to the investment landscape</a>.
The details of these transactions were disclosed in a Form 13F filing, a quarterly report required by the Securities and Exchange Commission for institutional investment managers overseeing more than $100 million in qualifying securities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998258/cathie-wood-keeps-betting-on-amazons-haul-play-ark-loads-up-6m-worth-of-shares">Cathie Wood Keeps Betting On Amazon&#8217;s &#8216;Haul&#8217; Play: Ark Loads Up $6M Worth Of Shares</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Asia

Equities

News

Markets

ETFs

AMZN

BABA

BEKE

BIDU

GOOG

KWEB

MSFT

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Billionaire David Tepper's China Puzzle: Appaloosa Cuts Alibaba Stake While Doubling Down On PDD

QUBT

Reported Earlier, Quantum Computing Secures $40M Through Registered Direct Offering, Pricing 16M Shares At $2.50 Each in At-the-Market Deal

Michael Saylor, CEO of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), deemed the Donald Trump-led Republican triumph the &#8220;biggest&#8221; bullish catalyst for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) over the last four years.
What Happened: In an interview with CNBC on Thursday, Saylor said that the &#8220;red wave&#8221; has been &#8220;incredibly auspicious&#8221; for Bitcoin and the broader cryptocurrency industry.
The Bitcoin bull anticipated a friendlier SEC at the helm amid speculations of current chair Gary Gensler stepping aside.
&#8220;It&#8217;s very good for the cryptocurrency industry. We&#8217;re going to see a lot more pro-Bitcoin policies. We are going to see a digital assets framework. We are going to see an end to the war on crypto.,&#8221; Saylor predicted.
Don&#8217;t Miss:
<ul>
<li>Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.</a></li>
<li>1 in 4 Americans own a share of Bitcoin according to NASDAQ — <a href="https://www.benzinga.com/money/binance-100">this platform touts returns as high as 12.5% APY and is giving $100 in welcome rewards if you sign up today.</a></li>
</ul>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&quot;The red wave is probably the biggest thing that has happened in the past four years for bitcoin&quot; &#8211; <a href="https://twitter.com/MicroStrategy?ref_src=twsrc%5Etfw">@MicroStrategy</a> founder &amp; chairman <a href="https://twitter.com/saylor?ref_src=twsrc%5Etfw">@saylor</a> on his crypto expectations under a second Trump presidency. <a href="https://t.co/9BYAYgLGe8">pic.twitter.com/9BYAYgLGe8</a>
&mdash; CNBCOvertime (@CNBCOvertime) <a href="https://twitter.com/CNBCOvertime/status/1857179737606459844?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
With the election uncertainty behind, Saylor also ruled out any major bearish events for Bitcoin in the foreseeable future.
&#8220;I am planning the $100,000 party, and I am thinking it is probably going to be New Year&#8217;s Eve at my house. So, I would be surprised if we don&#8217;t go through $100,000 in November or December,&#8221; Saylor said in a burst of enthusiasm.
See Also: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a>
Why It Matters: Saylor&#8217;s bullish sentiment aligned with the ongoing success of his company&#8217;s publicly-traded stock. 
MicroStrategy&#8217;s shares hit a record high earlier this week, pushing the firm&#8217;s market valuation to $72.26 billion, a $50 billion increase since September 6. This gain <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41961419/bitcoin-proxy-microstrategy-added-more-to-its-market-cap-in-last-2-months-than-what-ford-is-worth-currently">surpassed the total capitalization</a> of Ford Motor Co. (F) and Cognizant Technology Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>).
The firm, known famously as Bitcoin&#8217;s biggest corporate holder, was sitting on unrealized profits of over $12.7 billion as of this writing, <a href="https://bitcointreasuries.net/" target="_blank" rel="noreferrer noopener">according&nbsp;</a>to data from bitcointreasuries.net.&nbsp;&nbsp;
The company&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil" target="_blank" rel="noreferrer noopener">announced plans</a>&nbsp;to raise as much as $42 billion in equity and debt funding over the next three years to accumulate more Bitcoin.
Price Action: At the time of writing, Bitcoin was exchanging hands at $88,121.00, down 1.89% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>. Shares of MicroStrategy closed 0.22% lower at $327.67 during Thursday&#8217;s regular trading session.
Photo Courtesy: Wikimedia
Read Next: 
<ul>
<li>This well known prop trading firm is offering 100% of your first $25,000 profit per account and 90% after that. <a href="https://www.benzinga.com/money/apex-trader-funding">Here's how to get a special 50% OFF CODE that lets you start out with monthly investments as low as $147 today.</a></li>
<li>If you invested $100 in DOGE when Elon Musk first tweeted about it in 2019,<a href="https://www.benzinga.com/money/etoro-doge"> here&#8217;s how much you&#8217;d have today</a>.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CTSH

MSTR

Michael Saylor Is Planning A Bitcoin $100K Party At His House, Expects End Of War On Crypto Under Trump

AGAE

Reported Earlier, AGAE Responds To Knighted's Legal Claims, Alleging Roy Choi's Attempt To Undermine Board's Strategic Decisions For Short-Term Gains

Elon Musk&#8216;s SpaceX has been increasing its launch cadence, enabling 17 launches in the last 31 days, and exceeding its <a href="https://www.benzinga.com/news/24/01/36860379/one-month-into-2024-spacex-is-already-falling-short-of-its-own-launch-targets-temporary-setback-or-c">monthly launch targets</a>.
What Happened: SpaceX&#8217;s Falcon 9 rocket launched 24 Starlink satellites to low-Earth orbit from Florida on Thursday, marking its 17th launch in 31 days.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Falcon 9 lifts off from pad 40 in Florida, completing our 17th launch in 31 days! <a href="https://t.co/w0snRDcUA9">pic.twitter.com/w0snRDcUA9</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1857082099154456924?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SpaceX launched almost every other day in the last 31 days, exceeding its target set at the start of the year of 12 launches every month. 
However, the Musk-led space giant <a href="https://www.benzinga.com/news/24/07/39612042/elon-musks-spacex-launches-67-missions-in-first-half-of-2024-trailing-own-targets">fell short of its launch targets</a> in the first half of 2024, completing just 67 missions, not including its Starship test flights. The company is now trying to reach its launch target for the whole year by amping up launches in the remaining months.
Why It Matters: SpaceX has already exceeded 100 launches this year, outrunning its 96 launches in 2023. 
SpaceX VP of Launch Kiko Dontchev said earlier this month that the company will <a href="https://www.benzinga.com/news/24/11/41767169/spacex-completes-400th-successful-falcon-launch-to-date-but-will-miss-target-of-144-launches-in-2024">not make its goal of 144 launches this year</a> but is still targeting 30 more launches, or one launch every two days, for the rest of the year.
SpaceX is currently using its Falcon launch vehicles for the payload carrying missions. The company is also testing its Starship launch vehicle, whose next test flight is expected <a href="https://www.benzinga.com/general/space/24/11/41871398/spacex-aims-to-launch-starship-once-every-2-weeks-by-late-2025-ceo-elon-musk-says-we-will-be-much-faster">as early as Nov. 18</a>. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/partner/fintech/24/11/41939694/the-power-of-leverage-global-broker-octa-lays-out-the-ins-and-outs-of-this-trading-tool-for-trade">Ford Cuts Capri, Explorer EV Output Due To &#8216;Significantly Lower Than Expected Demand&#8217; After Pausing F-150 Lightning Production</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

SpaceX Speeds Up Mission Launches With A New One Taking Off Every Other Day Over Last Month As It Races Towards Its 2024 Target

The Share Repurchase is being made pursuant to the Company's existing $50.0 million share repurchase program. On November 14, 2024, the Company announced that its Board of Directors authorized a share repurchase program, beginning on the date thereof and continuing through and including December 31, 2025. After the completion of the Share Repurchase described above, there will be $35.0 million remaining under the Company's share repurchase program.

Kodiak Gas Prices Upsized Offering Of 5.7M Common Shares At $34.50/Share; Proceeds To Selling Stockholder, $15M Buyback To Follow

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Greed&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones falling more than 200 points during the session as investors digested recent economic reports.
U.S. initial jobless claims declined by 4,000 from the previous week to 217,000 in the week ending Nov. 9, compared to market estimates of 223,000. U.S. producer prices rose 0.2% month-over-month in October compared to a revised 0.1% gain in September, in line with market expectations.
Shares of Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell around 5.8% on Thursday after recording sharp gains in the recent period. The small-cap benchmark Russell 2000 tumbled over 1% during the session.
Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) shares fell over 2% on Thursday despite reporting better-than-expected results for its first quarter.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, industrials, and healthcare stocks recording the biggest losses on Thursday. However, information technology and energy stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 207 points to 43,750.86 on Thursday. The S&amp;P 500 fell 0.60% to 5,949.17, while the Nasdaq Composite fell 0.64% to close at 19,107.65 during Thursday's session.
Investors are awaiting earnings results from Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>), and RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 60.3, the index remained in the &#8220;Greed&#8221; zone on Thursday, versus a prior reading of 65.8.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Trading Ideas

CSCO

TSLA

Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In 'Greed' Zone

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
<ul>
<li>Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity</li>
<li>More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines</li>
<li>FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade &nbsp;</li>
</ul>

REGN

Dupixent's sBLA Resubmission Accepted By FDA; Phase 3 Data Demonstrate Significant Itch And Hive Reduction For Chronic Urticaria Patients

Wing, a drone business backed by Google-parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Apian, a British technology start-up, have launched a drone service for NHS blood sample deliveries in London.
What Happened:&nbsp;This new drone service, operating between Guy's and St Thomas' hospitals, reduces delivery time for blood samples from 30 minutes by van or motorbike to just 2 minutes, <a href="https://www.thetimes.com/article/dbd69ffe-252c-4d79-8f1f-ae9474f5b955">reported</a> The Times.
The drones are used to transport critical samples from patients at risk of bleeding disorders, helping to speed up decisions for surgeries and ensuring quick access to lab analysis.
Alphabet CEO Sundar Pichai took to X, formerly Twitter, and said, "Reducing blood sample delivery from 30 min to 2 min means faster results and quicker care for patients in critical need. Important use case for drone technology."
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/41894509/apples-next-big-bet-think-smaller-says-analyst-there-will-never-be-another-iphone?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple&#8217;s Next Big Bet? Think Smaller, Says Analyst: &#8216;There Will Never Be Another… iPhone&#8217;</a>
Guy's and St Thomas' NHS Foundation Trust have also backed this venture.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Reducing blood sample delivery from 30 min to 2 min (!) means faster results and quicker care for patients in critical need. Important use case for drone technology &#8211; well done to <a href="https://twitter.com/Wing?ref_src=twsrc%5Etfw">@Wing</a> <a href="https://twitter.com/Apianaero?ref_src=twsrc%5Etfw">@apianaero</a> <a href="https://twitter.com/NHSuk?ref_src=twsrc%5Etfw">@NHSuk</a> <a href="https://t.co/BPANo3Gr00">https://t.co/BPANo3Gr00</a>
&mdash; Sundar Pichai (@sundarpichai) <a href="https://twitter.com/sundarpichai/status/1857120784713654611?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters:&nbsp;This initiative comes after Alphabet reported a 15% year-over-year increase in <a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan">third-quarter revenue</a>, highlighting the company&#8217;s extraordinary momentum.
The drone project also aligns with Alphabet&#8217;s previous ventures into drone delivery services, such as its partnership with DoorDash in the U.S. to deliver food items.
Apian, which identifies itself as a <a href="https://www.benzinga.com/general/24/04/38088421/doordash-partners-with-googles-wing-for-drone-delivery-pilot-in-the-us-to-fly-food-to-your-front-doo">&#8220;healthcare logistics&#8221; business</a>, aims to become the &#8220;Deliveroo of medical transport&#8221;,&nbsp;creating a platform to match&nbsp;clinicians with urgent transport requests&nbsp;and commercial drone companies.
The company&nbsp;was founded in 2020 by&nbsp;Dr. Christopher Law, Dr. Hammad Jeilani, and&nbsp;Alexander Trewby, formerly of Google&nbsp;Health.
Price Action: As of the latest data, Alphabet's Class A shares declined 0.24% in after-hours trading to $175.15, while Class C shares slipped 0.20% to $177. In the regular session on Thursday, Class A and Class C shares closed at $175.58 and $177.35, respectively, according to<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener"> Benzinga Pro data</a>.
World Economic Forum on Flickr
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/24/11/41927913/amazon-confirms-vendor-data-breach-affecting-2-8m-employee-contacts-adds-to-growing-list-of-moveit-hack-victims?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amazon Confirms Vendor Data Breach Affecting 2.8M+ Employee Contacts, Adds To Growing List Of MOVEit Hack Victims</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Health Care

Media

GOOGL

Sundar Pichai Praises Google-Backed Apian Drones For Cutting Blood Sample Delivery Time From 30 To 2 Minutes: 'Quicker Care For Patients In Critical Need'

<ul>
<li>Afqlir&#xAE; (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)</li>
<li>One of several biosimilar value drivers for Sandoz</li>
<li>Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership</li>
</ul>

SDZNY

SDZXF

Sandoz Gains European Commission Approval For Afqlir (aflibercept), Targeting Wider Access Biosimilars In Europe

President-elect Donald Trump met Argentina President&nbsp;Javier Milei at his Mar-a-Lago resort Thursday. This was his first meeting with a world leader since winning the elections last week.
What Happened: Milei congratulated Trump on his election victory, lending support to the shared ideas of liberty and economic prosperity, <a href="https://www.bloomberg.com/news/articles/2024-11-15/argentine-president-milei-praises-trump-at-mar-a-lago-event?srnd=homepage-europe">Bloomberg</a> reported. 
"Today, the winds of freedom are blowing much stronger,"&nbsp;he said in Spanish at the America First Policy Institute event.&nbsp;&#8220;I am exhilarated to be able to share with the new U.S. administration the same level of freedom, and I'm convinced that together we will restore it to the place it deserves.
Milei, who assumed office a year ago, also praised tech mogul Elon Musk, who was in the audience, for promoting free speech through X. 
Trump, in turn, acknowledged Milei&#8217;s speech, stating, &#8220;Your speech was beautiful, but the job you've done is incredible.&#8221;
See Also: <a href="https://www.benzinga.com/24/11/41999143/microstrategy-ceo-michael-saylor-expects-more-pro-bitcoin-policies-under-incoming-trump-administration">Michael Saylor Is Planning A Bitcoin $100K Party At His House, Expects End Of War On Crypto Under Trump</a>
Why It Matters: Milei has earned praise from Trump for his economic policies. During an <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40329146/trump-praises-pro-bitcoin-argentina-president-javier-mileis-maga-like-economic-policies-in">interview</a> with Musk In August, the president-elect highlighted Argentina&#8217;s prosperity under Milei&#8217;s leadership, drawing parallels to his own &#8220;Make America Great Again&#8221; policy.
There has been significant bonhomie between Musk and Milei as well. The two met warmly in September <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40994028/elon-musk-dons-his-maga-hat-to-meet-pro-bitcoin-president-javier-milei-duo-discuss-argenti">on the sidelines</a> of Argentina&#8217;s national speech to the United Nations General Assembly.
Prior to that, Musk <a href="https://www.benzinga.com/24/09/40679115/elon-musk-praises-pro-bitcoin-president-javier-mileis-efforts-in-restoring-argentina-to-greatness-am">expressed his admiration</a> for Milei&#8217;s efforts in <a href="https://www.benzinga.com/24/09/40679115/elon-musk-praises-pro-bitcoin-president-javier-mileis-efforts-in-restoring-argentina-to-greatness-am">restoring Argentina&#8217;s stature</a>.
Milei secured victory in the November elections after promising large cuts in public spending to address Argentina&#8217;s fiscal deficit and increasing inflation. His libertarian stance is also reflected in his support for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), making him one of the very few heads of state to openly endorse the asset.
However, the president has also faced criticism for his austerity measures, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40825073/pro-bitcoin-president-javier-milei-triumphs-as-pension-spending-hike-stalled-in-argentinas" target="_blank" rel="noreferrer noopener">with many taking to the streets </a>to oppose his attempts to halt the increase in pension spending.
resident of the Republic of Armenia via Wikimedia Commons
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41993524/gary-gensler-hints-at-ending-his-stint-as-sec-chair-defends-crypto-regulation-agenda">Gary Gensler Hints At Ending His Stint As SEC Chair, Defends Crypto Regulation Agenda</a></li>
</ul>

Politics

Pro-Bitcoin Argentina President Javier Milei Becomes First Foreign Leader To Meet Trump: 'Winds Of Freedom Are Blowing Much Stronger'

Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) will release earnings results for its third quarter, before the <a href="https://www.benzinga.com/quote/NEXN/earnings">opening bell on Friday, Nov. 15.</a>
Analysts expect the Tel Aviv-Yafo, Israel-based bank to report quarterly earnings at 13 cents per share, down from 18 cents per share in the year-ago period. Nexxen projects to report revenue of $88.65 million for the recent quarter, compared to $80.09 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Aug. 22, Nexxen International posted better-than-expected sales for the second quarter.
Nexxen shares gained 1.9% to close at $7.67 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TCOM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/64da23ec2e59fb0001505ffd/matthew-swanson">RBC Capital analyst Matthew Swanson</a> maintained an Outperform rating and raised the price target from $9 to $11 on Aug. 23. This analyst has an accuracy rate of 62%.</li>
<li>Needham analyst Laura Martin maintained a Buy rating and raised the price target from $6.5 to $8.5 on Aug. 23. This analyst has an accuracy rate of 74%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/598858a9803ad30001474c48/andrew-boone">JMP Securities analyst Andrew Boone</a> reiterated a Market Outperform rating with a price target of $11 on June 14. This analyst has an accuracy rate of 61%.</li>
<li>Stifel analyst Mark Kelley maintained a Hold rating and raised the price target from $5.5 to $6 on May 21. This analyst has an accuracy rate of 88%.</li>
</ul>
Considering buying NEXN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="546" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15004101/image-161-1024x546.png" alt="" class="wp-image-649585" style="width:659px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15004101/image-161-1024x546.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15004101/image-161-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15004101/image-161-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15004101/image-161.png 1220w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>

Price Target

Analyst Ratings

NEXN

Top Wall Street Forecasters Revamp Nexxen International Price Expectations Ahead Of Q3 Earnings

Macro Economic Events

Econ #s

Economics

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan Industrial Production (MoM) For September 1.6% Vs. 1.4% Est.; 1.4% Prior

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) to report quarterly earnings at $2.1 per share on revenue of $33.95 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Alibaba shares rose 0.1% to $90.70 in after-hours trading.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) reported better-than-expected earnings for its fourth quarter. For the first quarter of fiscal 2025, Applied said it expects net revenue to be approximately $7.15 billion, plus or minus $400 million. Non-GAAP diluted EPS is expected to be approximately $2.29, plus or minus 18 cents. Applied Materials shares fell 6% to $174.90 in the after-hours trading session.</li>
<li>Analysts are expecting Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) to post quarterly earnings at $1.02 per share on revenue of $746.54 million. The company will release earnings before the markets open. Spectrum Brands shares gained 1.8% to $95.50 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Despegar.com, Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) reported better-than-expected third-quarter earnings and sales results on Thursday. The company said it sees FY24 revenue of at least $760 million and adjusted EBITDA of at least $170 million. Despegar.com shares jumped 13.4% to $16.85 in the after-hours trading session.</li>
<li>Analysts expect RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) to report quarterly earnings at 3 cents per share on revenue of $105.08 million before the opening bell. RLX Technology shares gained 0.6% to $1.64 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

AMAT

DESP

Alibaba, Applied Materials And 3 Stocks To Watch Heading Into Friday

Reported Earlier, Chinese Unemployment Rate For October 5.0% Vs. 5.1% Est.; 5.1% Prior

Reported Earlier, China Industrial Production Year to Date (YoY) For October 5.8% Vs. 5.8% Prior

Reported Earlier, China Industrial Production (YoY) For October 5.3% Vs. 5.5% Est.; 5.4% Prior

Reported Earlier, China Fixed Asset Investment (YoY) For October 3.4% Vs. 3.5% Est.; 3.4% Prior

Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) will release earnings results for its second quarter, before the <a href="https://www.benzinga.com/quote/BABA/earnings">opening bell on Friday, Nov. 15.</a>
Analysts expect the China-based company to report quarterly earnings at $2.1 per share on revenue of $33.95 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Alibaba Group, last month, decided to settle a class-action lawsuit filed by its shareholders for $433.5 million. The lawsuit alleged that the company had made misleading statements about its exclusivity practices.
Alibaba shares fell 1.5% to close at $90.58 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/598858a9803ad30001474c4d/james-lee">Mizuho analyst James Lee</a> maintained an Outperform rating and raised the price target from $92 to $113 on Nov. 12. This analyst has an accuracy rate of 83%.</li>
<li>Baird analyst Colin Sebastian maintained an Outperform rating and increased the price target from $88 to $110 on Oct. 24. This analyst has an accuracy rate of 81%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5804be1a846faa000106aa69/rob-sanderson">Loop Capital analyst Robert Sanderson</a> maintained a Buy rating with a price target of $115 on Aug. 29. This analyst has an accuracy rate of 71%.</li>
<li>Susquehanna analyst Shyam Patil maintained a Positive rating and cut the price target from $135 to $130 on Aug. 19. This analyst has an accuracy rate of 69%.</li>
<li>Truist Securities analyst Youssef Squali maintained a Buy rating and slashed the price target from $110 to $100 on Aug. 16. This analyst has an accuracy rate of 81%.</li>
</ul>
Considering buying BABA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15003733/image-160-1024x549.png" alt="" class="wp-image-649569" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15003733/image-160-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15003733/image-160-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15003733/image-160-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15003733/image-160.png 1227w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41971544/jim-cramer-recommends-microsoft-praises-american-water-works-for-being-consistent">Jim Cramer Recommends Microsoft, Praises American Water Works For Being &#8216;Consistent&#8217;</a></li>
</ul>

Alibaba Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Reported Earlier, Japan Gross Domestic Product Price Index (YoY) Preliminary For Q3 2.5% Vs. 2.8% Est.; 3.1% (Revised) Prior

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Penumbra (PEN – Research Report), Nurix Therapeutics (NRIX – Rese...

Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Nurix Therapeutics (NRIX) and Charles River Labs (CRL)

The latest announcement is out from Nurix Therapeutics ( ($NRIX) ). Nurix Therapeutics, a clinical-stage biopharmaceutical company, has appointed A...

Nurix Therapeutics Appoints Anil Kapur to Board

H.C. Wainwright analyst Robert Burns raised the firm's price target on Nurix Therapeutics (NRIX) to $30 from $26 and keeps a Buy rating on the shar...

Nurix Therapeutics price target raised to $30 from $26 at H.C. Wainwright

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $32.0...

Promising Prospects for Nurix Therapeutics: Buy Rating Backed by Strong Data on NX-5948

Needham analyst Gil Blum maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $29.00. Gil Blum ha...

Promising Data on Nurix Therapeutics' NX-5948 Supports Buy Rating for Waldenstrom's Macroglobulinemia Treatment

In a report released today, Peter Lawson from Barclays assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report), with a price target of...

Barclays Gives a Buy Rating to Nurix Therapeutics (NRIX)

UBS initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target The firm launched coverage of SMID cap biotech sector wi...

Nurix Therapeutics initiated with a Buy at UBS

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls

UBS launches SMID cap biotechs with cancer, autoimmunity in focus

Analyst Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price target at $29.00. Gil Bl...

Promising Efficacy and Safety of Nurix Therapeutics' NX-5948 Justifies Buy Rating

BPMC

CATX

CGEM

CGON

HAFC

IDYA

IMCR

IOVA

JANX

KURA

MRUS

NRIX

NUVL

SIRI

SNDX

Press Releases

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Small Cap

Opinion

Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Management

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

General

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

Comments

Nurix Therapeutics

Noticias

Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL